Federated Hermes Inc. Buys Shares of 5,993 TransMedics Group, Inc. $TMDX

Federated Hermes Inc. purchased a new position in TransMedics Group, Inc. (NASDAQ:TMDX) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 5,993 shares of the company’s stock, valued at approximately $672,000.

A number of other institutional investors have also recently bought and sold shares of the company. Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of TransMedics Group by 981.0% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock valued at $26,000 after buying an additional 206 shares during the last quarter. Salomon & Ludwin LLC acquired a new stake in TransMedics Group in the third quarter valued at approximately $28,000. Pilgrim Partners Asia Pte Ltd bought a new stake in TransMedics Group in the third quarter worth approximately $40,000. First Horizon Corp acquired a new position in shares of TransMedics Group during the 3rd quarter worth $43,000. Finally, Elevation Point Wealth Partners LLC bought a new position in shares of TransMedics Group during the 2nd quarter valued at $48,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on TMDX. Needham & Company LLC increased their target price on shares of TransMedics Group from $148.00 to $166.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Piper Sandler reissued an “overweight” rating on shares of TransMedics Group in a report on Monday, December 22nd. Morgan Stanley boosted their target price on TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 2nd. Jefferies Financial Group assumed coverage on TransMedics Group in a report on Monday, October 13th. They set a “buy” rating and a $145.00 price target on the stock. Finally, Wall Street Zen lowered shares of TransMedics Group from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $144.25.

Insider Activity at TransMedics Group

In related news, Director David Weill sold 5,000 shares of the stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total value of $693,200.00. Following the completion of the sale, the director owned 12,134 shares in the company, valued at approximately $1,682,257.76. This trade represents a 29.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Anil P. Ranganath sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $145.22, for a total value of $435,660.00. Following the completion of the transaction, the insider directly owned 13,955 shares of the company’s stock, valued at approximately $2,026,545.10. This trade represents a 17.69% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 8,920 shares of company stock worth $1,257,310. Company insiders own 7.00% of the company’s stock.

TransMedics Group Stock Up 4.2%

TMDX opened at $135.06 on Friday. The business has a 50 day moving average of $133.12 and a 200-day moving average of $124.49. The stock has a market capitalization of $4.62 billion, a price-to-earnings ratio of 54.68 and a beta of 2.06. The company has a current ratio of 7.69, a quick ratio of 7.13 and a debt-to-equity ratio of 1.43. TransMedics Group, Inc. has a 1-year low of $62.07 and a 1-year high of $156.00.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.